The present study aimed at investigating the possible role of the PPARγ activators Octa and the new compound (2Z,4E,6E)-2-methoxyocta-2,4,6-trienoic acid (A02), designed based on an in silico docking model built around the available structure of the PPARγ ligand-binding domain complexed with different ligands, in targeting keratinocyte-derived skin cancer. The gene discussed is PPARG; the disease is skin cancer.